Skip to main content

Table 3 Analysis of efficacy (N = 89)

From: Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)

Endpoint   95% CI
Response rate 10.1% 4.7-18.3%
Disease control rate 65.2% 54.3-75.0%
TTF 4.1 months 2.8-4.8 months
PFS 5.4 months 4.1-6.2 months
OS 14.5 months 11.8-17.0 months
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us